tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GMAB Stock Latest News

Genmab: Limited Epkinly Approval Risk and High-Value 2026 Pipeline Catalysts Support Buy Rating
RatingsGenmab: Limited Epkinly Approval Risk and High-Value 2026 Pipeline Catalysts Support Buy Rating
38m ago
GMAB
Truist maintains optimism for 2026 read-out after Genmab’s Phase 3 trial OS miss
PremiumThe Fly
Truist maintains optimism for 2026 read-out after Genmab’s Phase 3 trial OS miss
3h ago
GMAB
Genmab Reports Positive Phase 3 Progression-Free Survival Data for Epcoritamab in Relapsed/Refractory DLBCL
PremiumCompany Announcements
Genmab Reports Positive Phase 3 Progression-Free Survival Data for Epcoritamab in Relapsed/Refractory DLBCL
3h ago
6K
GMAB
AbbVie announces results for epcoritamab from Phase 3 EPCORE DLBCL-1 trial
PremiumThe Fly
AbbVie announces results for epcoritamab from Phase 3 EPCORE DLBCL-1 trial
4h ago
ABBV
GMAB
Genmab AS trading resumes
PremiumThe Fly
Genmab AS trading resumes
4h ago
GMAB
Genmab says OS in Phase 3 trial did not reach statistical significance
PremiumThe FlyGenmab says OS in Phase 3 trial did not reach statistical significance
4h ago
ABBV
GMAB
Genmab AS trading halted, news pending
Premium
The Fly
Genmab AS trading halted, news pending
4h ago
GMAB
Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank
Premium
The Fly
Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank
8d ago
GMAB
Genmab partners with Anthropic to accelerate R&D through agentic AI
PremiumThe Fly
Genmab partners with Anthropic to accelerate R&D through agentic AI
9d ago
GMAB
Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank
PremiumThe Fly
Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank
10d ago
GMAB
Genmab price target raised to DKK 2,500 from DKK 2,000 at Barclays
PremiumThe Fly
Genmab price target raised to DKK 2,500 from DKK 2,000 at Barclays
10d ago
GMAB
PremiumRatings
Genmab: Late-Stage Oncology Pipeline Catalysts Underpin Buy Rating and Upside Potential
10d ago
GMAB
Genmab discontinuing acasunlimab a ‘good decision,’ says Guggenheim
PremiumThe FlyGenmab discontinuing acasunlimab a ‘good decision,’ says Guggenheim
17d ago
GMAB
Genmab Drops Acasunlimab to Refocus Investment on Late-Stage Cancer Pipeline
Premium
Company Announcements
Genmab Drops Acasunlimab to Refocus Investment on Late-Stage Cancer Pipeline
18d ago
6K
GMAB
Genmab to discontinue clinical development of acasunlimab
Premium
The Fly
Genmab to discontinue clinical development of acasunlimab
18d ago
GMAB
Genmab to discontinue further development of acasunlimab
PremiumThe Fly
Genmab to discontinue further development of acasunlimab
18d ago
GMAB
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know
PremiumCompany Announcements
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know
21d ago
BNTX
GMAB
Genmab’s Rina-S: New Study Targets Lung Cancer with Innovative Treatment
PremiumCompany Announcements
Genmab’s Rina-S: New Study Targets Lung Cancer with Innovative Treatment
1M ago
GMAB
Genmab’s Mixed Prospects: Hold Rating Amid Promising Pipeline and Uncertainties
PremiumRatings
Genmab’s Mixed Prospects: Hold Rating Amid Promising Pipeline and Uncertainties
1M ago
GMAB
Genmab’s New Phase 3 Study: A Potential Game-Changer in Ovarian Cancer Treatment
PremiumCompany AnnouncementsGenmab’s New Phase 3 Study: A Potential Game-Changer in Ovarian Cancer Treatment
1M ago
GMAB
Genmab Completes Acquisition of Merus N.V. to Bolster Oncology Portfolio
Premium
Company Announcements
Genmab Completes Acquisition of Merus N.V. to Bolster Oncology Portfolio
1M ago
6K
GMAB
Genmab’s Promising Future: Buy Rating Backed by Strong R&D and Market Performance
Premium
Ratings
Genmab’s Promising Future: Buy Rating Backed by Strong R&D and Market Performance
1M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >